近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

HOWES N, LATTIMORE S, IRVING WL and THOMSON BJ, 2016. Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment. Open forum infectious diseases. 3(1), ofv218 ESLAM M, MANGIA A, BERG T, CHAN HL, IRVING WL, DORE GJ, ABATE ML, BUGIANESI E, ADAMS LA, NAJIM MA, MIELE L, WELTMAN M, MOLLISON L, CHENG W, RIORDAN S, FISCHER J, ROMERO-GOMEZ M, SPENGLER U, NATTERMANN J, RAHME A, SHERIDAN D, BOOTH DR, MCLEOD D, POWELL E, LIDDLE C, DOUGLAS MW, VAN DER POORTEN D, GEORGE J and , 2016. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology (Baltimore, Md.). 64(1), 34-46 FOSTER GR, IRVING WL, CHEUNG MC, WALKER AJ, HUDSON BE, VERMA S, MCLAUCHLAN J, MUTIMER DJ, BROWN A, GELSON WT, MACDONALD DC, AGARWAL K and , 2016. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of hepatology. 64(6), 1224-31 MARTIN NK, VICKERMAN P, BREW IF, WILLIAMSON J, MINERS A, IRVING WL, SAKSENA S, HUTCHINSON SJ, MANDAL S, O'MOORE E and HICKMAN M, 2016. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (Baltimore, Md.). 63(6), 1796-808 HUSSEIN NR, TUNJEL I, BASHARAT Z, TAHA A and IRVING W, 2016. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiology and infection. 144(8), 1634-40 CHEUNG MC, WALKER AJ, HUDSON BE, VERMA S, MCLAUCHLAN J, MUTIMER DJ, BROWN A, GELSON WT, MACDONALD DC, AGARWAL K, FOSTER GR, IRVING WL and , 2016. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of hepatology. 65(4), 741-7 ROBERTS K, MACLEOD J, METCALFE C, SIMON J, HORWOOD J, HOLLINGWORTH W, MARLOWE S, GORDON FH, MUIR P, COLEMAN B, VICKERMAN P, HARRISON GI, WALDRON CA, IRVING W and HICKMAN M, 2016. Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial. Trials. 17, 366 THABET K, ASIMAKOPOULOS A, SHOJAEI M, ROMERO-GOMEZ M, MANGIA A, IRVING WL, BERG T, DORE GJ, GRØNBÆK H, SHERIDAN D, ABATE ML, BUGIANESI E, WELTMAN M, MOLLISON L, CHENG W, RIORDAN S, FISCHER J, SPENGLER U, NATTERMANN J, WAHID A, ROJAS A, WHITE R, DOUGLAS MW, MCLEOD D, POWELL E, LIDDLE C, VAN DER POORTEN D, GEORGE J, ESLAM M and , 2016. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature communications. 7, 12757 IRVING, W. L., 2016. Viral Oncogenesis and Hepatocellular Carcinoma JOURNAL OF PATHOLOGY. 240, 10-10 SEVRAIN D, DUBREUIL M, DOLMAN GE, ZAITOUN A, IRVING W, GUHA IN, ODIN C and LE GRAND Y, 2015. Evaluation of area-based collagen scoring by nonlinear microscopy in chronic hepatitis C-induced liver fibrosis. Biomedical optics express. 6(4), 1209-18 URBANOWICZ, R. A., MCCLURE, C. P., BROWN, R. J., TSOLERIDIS, T., PERSSON, M. A., KREY, T., IRVING, W. L., BALL, J. K. and TARR, A. W., 2015. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance: J Virol J Virol. 90(7), 3288-301 ESLAM M, HASHEM AM, ROMERO-GOMEZ M, BERG T, DORE GJ, MANGIA A, CHAN HL, IRVING WL, SHERIDAN D, ABATE ML, ADAMS LA, WELTMAN M, BUGIANESI E, SPENGLER U, SHAKER O, FISCHER J, MOLLISON L, CHENG W, NATTERMANN J, RIORDAN S, MIELE L, KELAENG KS, AMPUERO J, AHLENSTIEL G, MCLEOD D, POWELL E, LIDDLE C, DOUGLAS MW, BOOTH DR, GEORGE J and , 2015. FibroGENE: A gene-based model for staging liver fibrosis. Journal of hepatology. 64(2), 390-8 PADAM P, CLARK S, IRVING W, GELLISSEN R, THOMSON E, MAIN J and COOKE GS, 2015. Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease. Journal of viral hepatitis. 23(2), 123-9 HULLEGIE SJ, ARENDS JE, RIJNDERS BJ, IRVING WL, SALMON D, PRINS M, WENSING AM, KLENERMAN P, LEBLEBICIOGLU H, BOESECKE C, ROCKSTROH JK and HOEPELMAN AI, 2015. Current knowledge and future perspectives on acute hepatitis C infection. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 21(8), 797.e9-797.e17 IRVING WL, GROTZINGER K, THEODORE D, DEMUTH D, RIZZETTO M, ROUGHLEY A and FORSSEN U, 2015. Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia. Journal of viral hepatitis. 22(5), 511 ESLAM M, HASHEM AM, LEUNG R, ROMERO-GOMEZ M, BERG T, DORE GJ, CHAN HL, IRVING WL, SHERIDAN D, ABATE ML, ADAMS LA, MANGIA A, WELTMAN M, BUGIANESI E, SPENGLER U, SHAKER O, FISCHER J, MOLLISON L, CHENG W, POWELL E, NATTERMANN J, RIORDAN S, MCLEOD D, ARMSTRONG NJ, DOUGLAS MW, LIDDLE C, BOOTH DR, GEORGE J, AHLENSTIEL G and , 2015. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature communications. 6, 6422 MARTIN, N. K., FOSTER, G. R., VILAR, J., RYDER, S., CRAMP, M. E., GORDON, F., DILLON, J. F., CRAINE, N., BUSSE, H., CLEMENTS, A., HUTCHINSON, S. J., USTIANOWSKI, A., RAMSAY, M., GOLDBERG, D. J., IRVING, W., HOPE, V., DE ANGELIS, D., LYONS, M., VICKERMAN, P. and HICKMAN, M., 2015. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact JOURNAL OF VIRAL HEPATITIS. 22(4), 399-408 OZARAS R, CORTI G, RUTA S, LACOMBE K, MONDELLI MU, IRWING WL, PUOTI M, KHALIGHI A, SANTOS ML, HARXHI A, LAZAREVIC I, SORIANO V, GERVAIN J, LEBLEBICIOGLU H, SALMON D, ARENDS JE and , 2015. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 21(11), 1027-32 GIRÓN-CALLEJAS A, CLARK G, IRVING WL and MCCLURE CP, 2014. In silico and in vitro interrogation of a widely used HEV RT-qPCR assay for detection of the species Orthohepevirus A. Journal of virological methods. 214C, 25-28 (In Press.) BACK X,M, LEWSZUK,A, WHITE , JR, COLE, J, SREEDHARAN , A, VAN SANDEN, S, DIELS,J, LAWSON ,A, NEAL, KR, WISELKA, MJ, ITO,T and IRVING,WL, 2014. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1 infected patients who do or do not achieve sustained virological response to therapy. Journal of Viral Hepatitis. 21, 208-215